Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.91
-0.4200-7.88%
Pre-market: 4.980.0700+1.43%04:00 EDT
Volume:705.80K
Turnover:3.57M
Market Cap:153.63M
PE:-1.19
High:5.41
Open:5.31
Low:4.89
Close:5.33
52wk High:50.40
52wk Low:4.54
Shares:31.29M
Float Shares:18.39M
Volume Ratio:0.99
T/O Rate:3.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.70
PE(LYR):-1.72

Loading ...

Autolus Therapeutics Announces FDA RMAT Designation Granted to Obe-cel for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis

GlobeNewswire
·
Yesterday

Summit Therapeutics upgraded to Buy at Jefferies ahead of PFS data

TIPRANKS
·
Yesterday

D. Western Therapeutics Sees FY Loss Y800.00m

Dow Jones
·
Yesterday

Neurizon Therapeutics Secures NIH Grant to Support Investigational ALS Treatment; Shares Up 31%

MT Newswires Live
·
Yesterday

Cyclerion Therapeutics trading halted, news pending

TIPRANKS
·
Yesterday

Press Release: Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting

Dow Jones
·
Yesterday

Structure Therapeutics: Buy Rating Reaffirmed on Promising Obesity Pipeline and Extended Data, Price Target Maintained at $104

TIPRANKS
·
Yesterday

Keros Therapeutics Announces Share Repurchase Authorization Program

TIPRANKS
·
Yesterday

Sangamo Therapeutics Completes Key Technology Asset Sale

TIPRANKS
·
Yesterday

Keros Therapeutics announces $5M share repurchase program after Takeda payment

TIPRANKS
·
Yesterday

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire
·
Yesterday

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

GlobeNewswire
·
Yesterday

Press Release: Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million

Dow Jones
·
Yesterday

ME Therapeutics Advances Dual-Target CAR and STING mRNA Programs as NASDAQ Plans Progress

TIPRANKS
·
Yesterday

Shares of Beam Therapeutics Retreat After Updated Trial Data Disappoints

Dow Jones
·
Yesterday

enGene Therapeutics Price Target Maintained with a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
Yesterday

Beam Therapeutics: Buy Rating Reiterated as BEAM-302 Data Strengthens Clinical Profile; $80 Price Target Maintained

TIPRANKS
·
Yesterday

TScan Therapeutics Cut to Neutral from Buy by HC Wainwright & Co.

Dow Jones
·
Sep 08

Beam Therapeutics: Buy Rating Backed by Strengthened BEAM-302 Clinical Profile and Clearer Accelerated Approval Path Despite Market Pullback

TIPRANKS
·
Sep 08

Beam Therapeutics falls -12.7%

TIPRANKS
·
Sep 08